InFocus Capital Partners

Stuart Therapeutics is a biotechnology company focused on developing PolyCol, a therapeutic platform designed for various ophthalmic conditions. This innovative platform utilizes a synthesized peptide to repair disease-damaged helical collagen in the eye, promoting accelerated healing of epithelial cells, restoring nerve function, and reducing inflammation. PolyCol addresses several ophthalmic indications, including dry eye disease, dry age-related macular degeneration, and glaucoma. The technology is rooted in patented research from a prominent U.S. university and is supported by additional intellectual property acquired by the company. In addition to ophthalmic applications, Stuart Therapeutics is exploring the use of PolyCol for gastrointestinal, inflammatory, and oncology conditions, aiming to provide new treatment options across a range of medical fields.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms to treat chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two main products: OcuLief, which provides long-term release of therapeutics for age-related macular degeneration and diabetic retinopathy, and EyeLief, designed for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers, enabling the delivery of various therapeutic molecules over periods ranging from one week to a year. Re-Vana's approach aims to enhance patient compliance through reduced treatment frequency and pain, while also minimizing side effects and healthcare costs.

Mojo Vision is a company based in Saratoga, California, that specializes in augmented reality products and platforms. Founded in 2015, it has developed a smart contact lens featuring a built-in display that provides timely information without disrupting the user's focus. This innovative technology enables users to receive immediate and relevant information, facilitating hands-free communication and interaction. By minimizing the distractions associated with traditional mobile devices, Mojo Vision aims to enhance connectivity and accessibility for users in various environments.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Pr3vent, Inc. is a technology company based in Palo Alto, California, focused on developing artificial intelligence and machine learning solutions for screening ophthalmic conditions in newborns. Founded in 2017, the company has created a non-invasive screening technology that utilizes algorithms to analyze images of infants' retinas. This technology is designed to detect abnormalities that could lead to preventable vision loss. By instantly identifying potential pathologies, Pr3vent's system enables healthcare professionals to initiate timely examinations and treatments, thus improving outcomes for affected infants.

Qura, Inc. specializes in the development of micro-injectable implants and ultra-miniature implantable devices designed to monitor physiological pressure changes. Founded in 2013 and headquartered in Framingham, Massachusetts, the company aims to revolutionize physiologic monitoring in biomedicine through innovative technology. Qura envisions a future where networks of smart, miniaturized tools can communicate and respond to one another in real-time, enabling both disease monitoring and timely treatment administration. The potential applications of these devices extend beyond clinical settings, promising significant advancements in research capabilities and patient care.

Alievio is a North Carolina-based innovative glaucoma medical device company. The company has introduced the first glaucoma therapy that will not only circumvent the complications present with glaucoma surgery. It also provides ophthalmologists with the first tool that can stop the progression of glaucoma.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.